CU23538B7 - Composiciones farmacéuticas para el tratamiento de enfermedades relacionadas a neurotrofinas - Google Patents

Composiciones farmacéuticas para el tratamiento de enfermedades relacionadas a neurotrofinas

Info

Publication number
CU23538B7
CU23538B7 CU20040289A CU20040289A CU23538B7 CU 23538 B7 CU23538 B7 CU 23538B7 CU 20040289 A CU20040289 A CU 20040289A CU 20040289 A CU20040289 A CU 20040289A CU 23538 B7 CU23538 B7 CU 23538B7
Authority
CU
Cuba
Prior art keywords
treatment
neurotrofins
iii
pharmaceutical compositions
general formula
Prior art date
Application number
CU20040289A
Other languages
English (en)
Inventor
Enrico Garaci
Maria Torcia
Federico Cozzolino
Antonio Guarna
Original Assignee
Mimetech S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mimetech S R L filed Critical Mimetech S R L
Publication of CU23538B7 publication Critical patent/CU23538B7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a preparaciones farmacéuticas que incluyen como compuestos activos derivados de 3-aza-biciclo [3.2.1] octanos de la fórmula general (I), y/o sus dímeros de la fórmula general (II) ó (III) que actúan como agonistas de las neurotrofinas humanas. Por lo tanto, estos compuestos de la fórmula (I), (II) y (III) son útiles para el tratamiento de enfermedades en las cuales están comprendidas en defecto las funciones de las neurotrofinas, particularmente del factor de Crecimiento de Nervios (NGF), tal como enfermedades neurodegenerativas del Sistema Nervioso Central (CNS), Inmunodeficiencia adquirida debido a una biodisponibilidad reducida de NGF, o condiciones mórbidas en las cuales es conveniente el estímulo del proceso de neoangiogénesis.
CU20040289A 2002-06-19 2004-12-16 Composiciones farmacéuticas para el tratamiento de enfermedades relacionadas a neurotrofinas CU23538B7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002FI000107A ITFI20020107A1 (it) 2002-06-19 2002-06-19 Composizioni farmaceutiche atte all'uso nel trattamento di patologie correlate all'azione di neutrofine e composti attivi in esse contenuti

Publications (1)

Publication Number Publication Date
CU23538B7 true CU23538B7 (es) 2010-06-17

Family

ID=29798543

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20040289A CU23538B7 (es) 2002-06-19 2004-12-16 Composiciones farmacéuticas para el tratamiento de enfermedades relacionadas a neurotrofinas

Country Status (21)

Country Link
US (1) US7625892B2 (es)
EP (1) EP1551412B1 (es)
JP (1) JP4728640B2 (es)
KR (1) KR101052345B1 (es)
CN (1) CN1662242B (es)
AT (1) ATE507833T1 (es)
AU (1) AU2003246559B2 (es)
CA (1) CA2489965C (es)
CU (1) CU23538B7 (es)
DE (1) DE60337019D1 (es)
DK (1) DK1551412T3 (es)
EA (1) EA014553B1 (es)
ES (1) ES2366117T3 (es)
IL (1) IL165787A (es)
IT (1) ITFI20020107A1 (es)
MX (1) MXPA04012494A (es)
NZ (1) NZ537791A (es)
PL (1) PL374372A1 (es)
PT (1) PT1551412E (es)
SI (1) SI1551412T1 (es)
WO (1) WO2004000324A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540957T1 (de) 2008-11-25 2012-01-15 Univ Firenze Bicyclische peptidomimetikum-inhibitoren von aspartylproteasen zur behandlung von infektionskrankheiten
ITRM20110024A1 (it) 2011-01-24 2012-07-25 Consiglio Nazionale Ricerche Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche.
ITFI20120062A1 (it) * 2012-03-21 2013-09-22 Minerva Patents S A Componenti per il trattamento di malattie correlate a ischemia-riperfusione.
ITFI20130304A1 (it) * 2013-12-24 2015-06-25 Univ Firenze Bicyclic peptidomimetics for use in the treatment of fungal infections
CN109867686A (zh) * 2017-12-05 2019-06-11 中国科学院大连化学物理研究所 一种制备6,8-二氧-2-氮杂二环[3,2,1]辛-2-烯衍生物的方法
IT202000008125A1 (it) 2020-04-16 2021-10-16 Minerva Srl Acidi carbossilici 3-aza-biciclo[3.2.1]ottani e loro derivati per l’uso nel trattamento di infiammazioni
IT202200016614A1 (it) 2022-08-04 2024-02-04 Mimetech S R L Udonitrectag e sue formulazioni ad uso topico per l’uso nel trattamento di patologie dermatologiche

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75910B (es) * 1981-04-21 1984-08-02 Delalande Sa
FR2504141A1 (fr) * 1981-04-21 1982-10-22 Delalande Sa Nouveaux derives dioxazabicycliques, leur procede de preparation et leur application en therapeutique
DE60042585D1 (de) * 2000-02-29 2009-09-03 Univ Firenze 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken

Also Published As

Publication number Publication date
JP4728640B2 (ja) 2011-07-20
CA2489965A1 (en) 2003-12-31
EA200401520A1 (ru) 2005-12-29
AU2003246559B2 (en) 2009-05-28
AU2003246559A1 (en) 2004-01-06
PL374372A1 (en) 2005-10-17
MXPA04012494A (es) 2005-06-08
DK1551412T3 (da) 2011-08-15
CN1662242B (zh) 2010-12-22
KR101052345B1 (ko) 2011-07-27
PT1551412E (pt) 2011-08-22
US7625892B2 (en) 2009-12-01
CN1662242A (zh) 2005-08-31
IL165787A0 (en) 2006-01-15
EP1551412B1 (en) 2011-05-04
HK1080380A1 (en) 2006-04-28
KR20050024352A (ko) 2005-03-10
EP1551412A1 (en) 2005-07-13
ATE507833T1 (de) 2011-05-15
NZ537791A (en) 2007-03-30
EA014553B1 (ru) 2010-12-30
CA2489965C (en) 2012-07-31
ES2366117T3 (es) 2011-10-17
WO2004000324A1 (en) 2003-12-31
SI1551412T1 (sl) 2011-09-30
IL165787A (en) 2014-04-30
ITFI20020107A1 (it) 2003-12-19
JP2005530834A (ja) 2005-10-13
US20060069092A1 (en) 2006-03-30
DE60337019D1 (de) 2011-06-16

Similar Documents

Publication Publication Date Title
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
WO2005113494A3 (en) Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
BR0206435A (pt) Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos
CA3103432A1 (en) Compounds for inhibition of inflammation
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
TW200502221A (en) Novel lactams and uses thereof
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
ATE428711T1 (de) Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon
MX2023006881A (es) Antagonistas del receptor de adenosina a2a.
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
EP1725536B8 (en) Imidazoline derivatives having cb1-antagonistic activity
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
PT1165544E (pt) 1,4-di-hidroindeno¬1,2-c|pirazoles substituidos como inibidores de tirosina-quinase
EA200401520A1 (ru) Фармацевтические композиции для лечения заболеваний, связанных с нейротрофинами
BR9811348A (pt) Compostos derivados de indol, processo para preparação dos mesmos, e, composições farmacêuticas.
ATE425756T1 (de) Verwendung von carbamazepinderivaten zur behandlung von agitatio in demenspatienten
MEP59108A (en) Memno peptides, a process for their preparation and their use
ATE496896T1 (de) 1h-imidazolderivate als modulatoren des cannabinoidrezeptors
DE602004014115D1 (de) Neue amidderivate von 2,2,3,3-tetramethylcyclopropancarbonsäure
DE60312154D1 (de) 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten

Legal Events

Date Code Title Description
FG Grant of patent